BCL11B Antikörper
-
- Target Alle BCL11B Antikörper anzeigen
- BCL11B (B-Cell CLL/lymphoma 11B (Zinc Finger Protein) (BCL11B))
-
Reaktivität
- Human
-
Wirt
- Ratte
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser BCL11B Antikörper ist unkonjugiert
-
Applikation
- Flow Cytometry (FACS)
- Kreuzreaktivität
- Maus, Zebrafisch
- Kreuzreaktivität (Details)
- Mouse, Zebrafish
- Aufreinigung
- Protein G affinity purified.
- Klon
- 25B6
- Isotyp
- IgG
- Top Product
- Discover our top product BCL11B Primärantikörper
-
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Buffer
- Hepes-buffered solution, pH 7.5, 0.02 % Sodium azide .
- Lagerung
- 4 °C
- Informationen zur Lagerung
- Upon receipt, store undiluted between 2°C and 8°C.
-
- Target
- BCL11B (B-Cell CLL/lymphoma 11B (Zinc Finger Protein) (BCL11B))
- Andere Bezeichnung
- Bcl11b (BCL11B Produkte)
- Hintergrund
- The transcription factor Bcl11b is expressed in thymus, mainly T cells. It is indispensable for T lineage development. When Bcl11b was deleted, T cells from all developmental stages acquired NK cell properties and concomitantly lost or decreased T cell-associated gene expression. These induced T-to-natural killer (ITNK) cells, which were morphologically and genetically similar to conventional NK cells, killed tumor cells in vitro, and effectively prevented tumor metastasis in vivo. Therefore, ITNKs may represent a new cell source for cell-based therapies.
-